Faculty Opinions recommendation of Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.

2015 ◽  
Author(s):  
Carla Greenbaum ◽  
Sandra Lord
Keyword(s):  
Type 1 Diabetes ◽  
Cell Function ◽  
Β Cell ◽  
Β Cell Function

Association of T-cell reactivity with β-cell function in recent onset type 1 diabetes patients

2010 ◽  
Vol 34 (2) ◽  
pp. 127-135 ◽  
Author(s):  
Christian Pfleger ◽  
Guido Meierhoff ◽  
Hubert Kolb ◽  
Nanette C. Schloot
Keyword(s):  
Type 1 Diabetes ◽  
T Cell ◽  
Cell Function ◽  
Β Cell ◽  
Cell Reactivity ◽  
Recent Onset ◽  
Onset Type ◽  
Β Cell Function ◽  
T Cell Reactivity

scholarly journals Autoreactive T effector memory differentiation mirrors β cell function in type 1 diabetes

2018 ◽  
Vol 128 (8) ◽  
pp. 3460-3474 ◽  
Author(s):  
Lorraine Yeo ◽  
Alyssa Woodwyk ◽  
Sanjana Sood ◽  
Anna Lorenc ◽  
Martin Eichmann ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cell Function ◽  
Effector Memory ◽  
Β Cell ◽  
Β Cell Function ◽  
Memory Differentiation

scholarly journals Residual β-cell function after 10 years of autoimmune type 1 diabetes: prevalence, possible determinants, and implications for metabolism

2021 ◽  
Vol 9 (8) ◽  
pp. 650-650
Author(s):  
Jin Cheng ◽  
Min Yin ◽  
Xiaohan Tang ◽  
Xiang Yan ◽  
Yuting Xie ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cell Function ◽  
Diabetes Prevalence ◽  
Β Cell ◽  
Β Cell Function

scholarly journals Systemic TNFα correlates with residual β-cell function in children and adolescents newly diagnosed with type 1 diabetes

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Anne Julie Overgaard ◽  
Jens Otto Broby Madsen ◽  
Flemming Pociot ◽  
Jesper Johannesen ◽  
Joachim Størling
Keyword(s):  
Type 1 Diabetes ◽  
Cell Function ◽  
Disease Onset ◽  
Newly Diagnosed ◽  
Β Cell ◽  
Entire Study ◽  
C Peptide ◽  
Disease Remission ◽  
Β Cell Function

Abstract Background Type 1 diabetes (T1D) is caused by immune-mediated destruction of the β-cells. After initiation of insulin therapy many patients experience a period of improved residual β-cell function leading to partial disease remission. Cytokines are important immune-modulatory molecules and contribute to β-cell damage in T1D. The patterns of systemic circulating cytokines during T1D remission are not clear but may constitute biomarkers of disease status and progression. In this study, we investigated if the plasma levels of various pro- and anti-inflammatory cytokines around time of diagnosis were predictors of remission and residual β-cell function in children with T1D followed for one year after disease onset. Methods In a cohort of 63 newly diagnosed children (33% females) with T1D with a mean age of 11.3 years (3.3–17.7), ten cytokines were measured of which eight were detectable in plasma samples by Mesoscale Discovery multiplex technology at study start and after 6 and 12 months. Linear regression models were used to evaluate association of cytokines with stimulated C-peptide. Results Systemic levels of tumor necrosis factor (TNF)-α, interleukin (IL)-2 and IL-6 inversely correlated with stimulated C-peptide levels over the entire study (P < 0.05). The concentrations of TNFα and IL-10 at study start predicted stimulated C-peptide level at 6 months (P = 0.011 and P = 0.043, respectively, adjusted for sex, age, HbA1c and stage of puberty). Conclusions In recent-onset T1D, systemic cytokine levels, and in particular that of TNFα, correlate with residual β-cell function and may serve as prognostic biomarkers of disease remission and progression to optimize treatment strategies. Trial Registration The study was performed according to the criteria of the Helsinki II Declaration and was approved by the Danish Capital Region Ethics Committee on Biomedical Research Ethics (journal number H-3-2014-052). The parents of all participants gave written consent.

scholarly journals Postexercise Glycemic Control in Type 1 Diabetes Is Associated With Residual β-Cell Function

Diabetes Care ◽  
2020 ◽  
Vol 43 (10) ◽  
pp. 2362-2370 ◽  
Author(s):  
Guy S. Taylor ◽  
Kieran Smith ◽  
Tess E. Capper ◽  
Jadine H. Scragg ◽  
Ayat Bashir ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Cell Function ◽  
Β Cell ◽  
Β Cell Function

scholarly journals Exercise to preserve β-cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial

2017 ◽  
Vol 34 (11) ◽  
pp. 1521-1531 ◽  
Author(s):  
P. Narendran ◽  
N. Jackson ◽  
A. Daley ◽  
D. Thompson ◽  
K. Stokes ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Cell Function ◽  
Pilot Trial ◽  
Β Cell ◽  
Recent Onset ◽  
Randomized Controlled ◽  
Β Cell Function

scholarly journals Preserved β-Cell Function in Type 1 Diabetes by Mesenchymal Stromal Cells

Diabetes ◽  
2014 ◽  
Vol 64 (2) ◽  
pp. 587-592 ◽  
Author(s):  
Per-Ola Carlsson ◽  
Erik Schwarcz ◽  
Olle Korsgren ◽  
Katarina Le Blanc
Keyword(s):  
Type 1 Diabetes ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Cell Function ◽  
Β Cell ◽  
Β Cell Function

scholarly journals Complex Multi-Block Analysis Identifies New Immunologic and Genetic Disease Progression Patterns Associated with the Residual β-Cell Function 1 Year after Diagnosis of Type 1 Diabetes

PLoS ONE ◽  
2013 ◽  
Vol 8 (6) ◽  
pp. e64632 ◽  
Author(s):  
Marie Louise Max Andersen ◽  
Morten Arendt Rasmussen ◽  
Sven Pörksen ◽  
Jannet Svensson ◽  
Jennifer Vikre-Jørgensen ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Disease Progression ◽  
Genetic Disease ◽  
Cell Function ◽  
Β Cell ◽  
Β Cell Function ◽  
Progression Patterns

β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

The Lancet ◽  
2001 ◽  
Vol 358 (9295) ◽  
pp. 1749-1753 ◽  
Author(s):  
Itamar Raz ◽  
Dana Elias ◽  
Ann Avron ◽  
Merana Tamir ◽  
Muriel Metzger ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Cell Function ◽  
Phase Ii Trial ◽  
Β Cell ◽  
Double Blind ◽  
Β Cell Function ◽  
New Onset

scholarly journals Genetic Composition and Autoantibody Titers Model the Probability of Detecting C-Peptide Following Type 1 Diabetes Diagnosis

2021 ◽  
Author(s):  
MacKenzie D. Williams ◽  
Rhonda Bacher ◽  
Daniel J. Perry ◽  
C. Ramsey Grace ◽  
Kieran M. McGrail ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Disease Duration ◽  
Cell Function ◽  
Age At Onset ◽  
Diabetes Diagnosis ◽  
Β Cell ◽  
C Peptide ◽  
Peptide Detection ◽  
Β Cell Function

We and others previously demonstrated that a type 1 diabetes genetic risk score (GRS) improves the ability to predict disease progression and onset in at-risk subjects with islet autoantibodies. Here, we hypothesized that GRS and islet autoantibodies, combined with age at onset and disease duration, could serve as markers of residual β-cell function following type 1 diabetes diagnosis. Generalized estimating equations were used to investigate whether GRS along with insulinoma-associated protein-2 autoantibody (IA-2A), zinc transporter 8 autoantibody (ZnT8A) and GAD autoantibody (GADA) titers were predictive of C-peptide detection in a largely cross-sectional cohort of 401 subjects with type 1 diabetes (duration median = 4.5 years, range 0-60). Indeed, a combined model incorporating disease duration, age at onset, GRS, and titers of IA-2A, ZnT8A and GADA provided superior capacity to predict C-peptide detection (QIC=334.6) compared with disease duration, age at onset, and GRS as the sole parameters (QIC=359.2). These findings support the need for longitudinal validation of our combinatorial model. The ability to project the rate and extent of decline in residual C-peptide production for individuals with type 1 diabetes could critically inform enrollment and benchmarking for clinical trials seeking to preserve or restore endogenous β-cell function.

Sign in / Sign up

Export Citation Format

Share Document